Best Clinical Genomics Companies in San Francisco, United States
The 38 best Clinical Genomics companies in San Francisco, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Helix.
Ranked: Best Clinical Genomics companies in San Francisco
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Helix Provider of a genomic database for clinical research | $435M | 63 mo ago | 265 | James Lu CEO | SanityApple iCloud MailNode.js+19 | 48 patents Genomic sequencing data management and cardiac genomics diagnostics analytics | 1 partnership |
| 2 | Inflammatix Provider of diagnostic solutions for systemic infections 74Funding top 17%Patents top 22%Growth top 26%Innovation top 27% All 10 signals ▾Fundingtop 17% Patentstop 22% Growthtop 26% Innovationtop 27% Moattop 28% Talenttop 35% Techtop 43% Marketbottom 45% Globalbottom 42% Newsbottom 18% Funding: Raised $191M across 11 rounds · 11 rounds over 9 yrs (1.2/yr) Patents: 52 patents matched (strict assignee match) · 36 filings since 2022 vs 16 in 2017-21 rank vs industry peers · Fliar Intelligence Index 74/100 | $191M | 24 mo ago | 54 54 → 75 (+39%) | Jonathan Romanowsky Co-Founder and Chief Business Officer | WordPressMySQLPHP+24 | 52 patents RNA-based rapid molecular diagnostic platforms for infectious and cardiac disease detection | 2 partnerships |
| 3 | Invitae Provider of home-based genetic test for individuals | $190M | 65 mo ago | 1,700 | Michele Cargill Co-Founder | ContentfulApple iCloud MailNode.js+22 | 108 patents Patents concentrated in computing, sensing & instrumentation | — |
| 4 | AudentesTherapeutics Developer of therapeutics to treat rare genetic diseases | $138M | 130 mo ago | 404 | — | — | — | — |
| 5 | Crescendo Bioscience CLIA Laboratory focused on autoimmune and inflammatory diseases | $122M | 164 mo ago | 128 | — | — | — | — |
| 6 | Veracyte Developer of genomics-based diagnostics for cancer | $113M | 125 mo ago | 815 815 → 722 (-11%) | — | WordPressApple iCloud MailElasticsearch+29 | 221 patents Patents concentrated in chemistry & materials | — |
| 7 | Counsyl DNA mapping for pre-pregnancy genetic testing, DNA and cancer screening | $113M | 106 mo ago | 503 | — | — | 134 patents Automated high‑throughput genetic testing and non‑invasive prenatal DNA screening platforms | 4 launchs · 1 award |
| 8 | uBiome Provider of sequence dataset of human microbiome | $110M | 95 mo ago | 33 | — | — | 320 patents Microbiome sequencing, analysis, and CRISPR-based diagnostics/therapeutics development | — |
| 9 | Adela Developer of a platform for detection of cancer 57Funding top 22%Moat top 31%Patents top 38%Talent top 38% All 8 signals ▾Fundingtop 22% Moattop 31% Patentstop 38% Talenttop 38% Markettop 46% Innovationtop 49% Globalbottom 40% Newsbottom 22% Funding: Raised $109M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 15 patents rank vs industry peers · Fliar Intelligence Index 57/100 | $109M | 5 mo ago | 62 | Manish Agarwal Co-Founder | — | 15 patents Patents concentrated in chemistry & materials | 1 partnership |
| 10 | Presidio Pharmaceuticals Developer of small-molecule antiviral therapeutics | $92M | 147 mo ago | 12 | Omar Haffar Co-Founder | — | 177 patents Antiviral heterocyclic compounds targeting hepatitis C virus NS5A protein | — |
| 11 | Mirvie Provider of non-invasive diagnostic tests for pregnant women 69Growth top 20%Funding top 21%Patents top 24%Talent top 28% All 9 signals ▾Growthtop 20% Fundingtop 21% Patentstop 24% Talenttop 28% Innovationtop 32% Moattop 36% Techtop 46% Globalbottom 40% Marketbottom 35% Growth: Headcount 23 → 35 (+52%) across vintages · Fresh capital in last 24 mo Funding: Raised $90.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 69/100 | $90M | 13 mo ago | 35 35 → 41 (+17%) | Mads Melbye Co-Founder | WebflowReactTypekit+21 | 49 patents Non‑invasive prenatal diagnostics using methylation and RNA biomarkers with AI analysis. | — |
| 12 | Miroculus Developer of MicroRNA profiling platform to detect genes in the sample | $48M | 66 mo ago | 26 | Fay Christodoulou Co-Founder & CSO | — | 123 patents Digital microfluidic droplet manipulation platforms for biochemical analysis and DNA synthesis. | — |
| 13 | Mantra Bio Developer of exosomes to deliver safe, highly targeted medicines | $44M | 44 mo ago | 17 | Terry Gaige Co-Founder And Vp Automation | — | — | — |
| 14 | Sequenta Immune medicine company decoding the adaptive immune system for disease treatment | $43M | 142 mo ago | 58 | Thomas Willis Co-Founder | — | 139 patents Immune repertoire sequencing and clonotype-based biomarker detection for disease monitoring | — |
| 15 | Siolta Therapeutics Provider of microbiome therapeutics for treating multiple diseases | $42M | 30 mo ago | 14 | Nikole Kimes Founder & CEO | — | — | — |
| 16 | Xcell Biosciences Developer of cell culture analysis device for cancer research | $40M | 21 mo ago | 11 11 → 17 (+55%) | — | WixSentryBootstrap+17 | 50 patents Precision gas‑liquid bioreactor platforms for phenotype‑controlled cell culture | — |
| 17 | Delve Bio Developer of sequencing platform to detect neuro-infectious pathogens | $35M | 38 mo ago | 2 | Bradley Murray Founder & CEO | — | — | — |
| 18 | Cofactor Genomics Developer of diagnostic assays using RNA sequencing 48Funding top 30%Moat top 32%Growth top 35%Tech top 39% All 11 signals ▾Fundingtop 30% Moattop 32% Growthtop 35% Techtop 39% AItop 45% Patentstop 46% Talentbottom 49% Innovationbottom 47% Globalbottom 40% Marketbottom 22% Newsbottom 18% Funding: Raised $26.2M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $26M | 8 mo ago | 9 | Jarret Glasscock Chief Executive Officer | WordPressApple iCloud MailGoogle Workspace+35 | 24 patents AI-driven analysis of NGS data for immuno‑oncology and circular nucleic‑acid engineering | — |
| 19 | Fluxion Biosciences Provider of microfluidics-based tools for cellular analysis | $21M | 83 mo ago | 13 | — | — | — | — |
| 20 | Phylagen Provider of genome sequencing technology for microbial analysis | $14M | 90 mo ago | 44 | Peter Karlen CEO & Board of Directors | — | 10 patents Microbial detection and environmental microbiome monitoring for facility safety and product traceability | — |
| 21 | InsightRx Analytics platform for precision dosing | $13M | 30 mo ago | 19 19 → 31 (+63%) | — | HubSpot CMS Hubcore-jsPreact+17 | — | — |
| 22 | Linkage Biosciences Life sciences solutions provider, enabling scientific research, discovery, and diagnostics | $13M | 160 mo ago | 34 | — | — | — | — |
| 23 | Cirina Innovating cancer detection for early, curable treatment through advanced technology | $12M | 111 mo ago | 491 | Rossa Chiu Co-Founder | — | 4 patents Cancer diagnostic assays analyzing nucleic acid fragments for tumor detection | — |
| 24 | Wave 80 Biosciences Instruments and consumables for infectious diseases | $3M | 172 mo ago | — | Dan Laser CEO & Founder | — | — | — |
| 25 | Prime Genomics Breast cancer diagnostics using saliva samples | $1M | 63 mo ago | — | Robert Feldman CEO & President | — | 16 patents Molecular cancer diagnostics and computational quantification of complex network dynamics | — |
| 26 | Advanced Genetic Systems Developer of Ribonucleoprotein complex based antiviral therapeutics for HIV treatment | $848K | 212 mo ago | — | Alan Frankel Founder | — | — | — |
| 27 | CASPR Biotech Developer of Cas-based diagnostics platform | $400K | 74 mo ago | 20 | Franco Goytia Co-Founder & CEO | WordPress Block EditorWordPressMySQL+14 | — | — |
| 28 | Coral Genomics Provider of genomic data based drug development | $150K | 19 mo ago | 1 | — | — | — | — |
Top 12 Clinical Genomics companies in San Francisco
#1
Series A · San Francisco, California · founded 2021 · 62 employees$108.5Mraised▾
Developer of a platform for detection of cancer. The company has developed a blood test for genome-wide methylation analysis technology to detect kidney cancer and intracranial brain tumors. It allows distinguishing the informative methylated regions of the genome from non-informative regions and targets for sequencing.
- Apr 2026Series A$5M
- Jun 2025Series A$25.4M
- Jul 2023Series A$48.5M
- Jun 2021Series A$60M
#2
Series A · San Francisco, California · founded 2009 · 9 employees$26.2Mraised▾
Developer of diagnostic assays using RNA sequencing. The company's product includes ImmunoPrism is an RNA sequencing-based assay that uses predictive immune modeling to generate multidimensional biomarkers. It combines machine learning and RNA-sequencing to build gene expression models for immune cells. The company's models for key immune cells include Immune Health Expression Models, Immune Escape Genes, and Co-inhibitory molecules. The company's sequencing products include mRNAble, Total RNAble, picoRNA, FFPExact, miRNAble, RNAccess, RNAmplify, and RNAdvantage.
- Dec 2025Series A—
- Aug 2023Series A$1.2M
- Dec 2021Series A$6.9M
- Jun 2017Series A$18M
#3
Series B · San Francisco, California · founded 2019 · 35 employees$90Mraised▾
Provider of non-invasive diagnostic tests for pregnant women. The company offers blood test-based diagnostics to predict the fetal development and health conditions of prenatal babies. They perform the detection of nine cell-free RNA (cfRNA) which help in measuring the gestational age of the fetal. The other non-invasive tests in which the maternal blood is analyzed for the cRNA to detect the preterm risk management solutions(advance of labor) in women.
- Jul 2025Series B$23.7M
- Aug 2023Grant (prize money)$4.6M
- May 2022Conventional Debt—
- May 2022Series B$60M
#4
Series E · San Francisco, California · founded 2016 · 54 employees$191.5Mraised▾
Provider of diagnostic solutions for systemic infections. Its proprietary technology, based on research from Stanford University, measures gene expression patterns related to the immune system to diagnose sepsis. It provides products such as InSep for acute infection and sepsis tests, ViraBac for acute infection tests, SARC-CoV-2 swabs, etc.
- Sep 2024Series E$57M
- Jul 2023Grant (prize money)$299.8K
- Nov 2021Grant (prize money)$12.1M
- Nov 2021Grant (prize money)$1.7M
#5
Series B · San Francisco, California · founded 2012 · 11 employees$39.5Mraised▾
Developer of cell culture analysis device for cancer research. The platform technology Avatar mimics in vivo physiological conditions for reproducible and more accurate in vitro tests. It allows for the preferential isolation and expansion of circulating tumor cells in the patient's blood. The company also provides cell-binding substrates and culture media to use in conjunction with its platform. The company has developed a cell analysis tool which is AI enables and assists with real-time analysis of cell health for identifying cell kinetics, targets, and other immunotherapy research.
- Dec 2024Series B$1.4M
- Jan 2022Series B$27.5M
- Feb 2017Series A$12M
- Jul 2015Seed—
#6
Series C · San Francisco, California · founded 2016 · 14 employees$42Mraised▾
Provider of microbiome therapeutics for treating multiple diseases. The company is focusing on the development of targeted human microbiome therapeutics for the prevention and treatment of chronic inflammatory diseases, starting with allergic diseases. The company's flagship product is STMC-103H for treating atopic dermatitis, food allergy, and allergic asthma.
- Mar 2024Series C$12M
- Aug 2023Grant (prize money)$300K
- Feb 2022Grant (prize money)$2.9M
- Sep 2020Series B$30M
#7
Series E · San Francisco, California · founded 2015 · 265 employees$435Mraised▾
Provider of a genomic database for clinical research. The company has a proprietary clinical-genomic database of Exome+ sequencing data and deep phenotypic data that can be used to accelerate the drug development lifecycle from discovery to commercialization. It offers data analytics platforms for health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision-making.
- Jun 2021Series E$50M
- Jul 2020Grant (prize money)$33M
- Mar 2018Series E$200M
- Apr 2017Series D$185M
#8
Public · San Francisco, California · founded 2010 · 1700 employees$189.6Mraised▾
Provider of home-based genetic tests for individuals. The platform enables users to request a test online with the help of doctors to collect saliva samples to detect genetic diseases. Users can get results online and share them with doctors.
- Apr 2021Post IPO$1.1B
- Jul 2020Post IPO$475M
- Sep 2019Post IPO$350M
- Nov 2018Conventional Debt$200M
#9
Series A · San Francisco, California · founded 2015 · 19 employees$13.2Mraised▾
InsightRX, a precision medicine company founded in 2015, offers to optimize drug dosage for the individual patient. Efforts in precision medicine, currently, focuses only on selecting the right drug for the right patient and drug dosage is overlooked. According to the company, its InsightRX software platform provides an informed patient-specific dose by leveraging machine learning, mathematical models, patient demographics, physiological characteristics, pharmacogenomic data, drug concentrations and biomarkers. The company caters to Clinical Pharmacists and Physicians and aims at reducing adverse events, improving outcomes and reducing hospital costs.
- Feb 2024Conventional Debt—
- Sep 2019Series A$10M
- May 2017Series A$3.2M
#10
Series A · San Francisco, California · founded 2022 · 2 employees$35Mraised▾
Developer of sequencing platform to detect neuro-infectious pathogens. The company leverages mNGS (metagenomic sequencing) to provide labs and clinicians with the necessary results for diagnosing infectious diseases such as bacterial, viral, fungal, and parasitic species.
- Jun 2023Series A$35M
#11
Series A · San Francisco, California · founded 2016 · 17 employees$44.1Mraised▾
Developer of exosomes to deliver safe, highly targeted medicines. The company has developed REVEAL, an exosome engineering platform combining computational biology and lab automation to generate targeted exosome vehicles (TEVs) for a broad set of therapeutic areas.
- Jan 2023Series A$9M
- Jul 2020Series A$30.1M
- Jun 2017Seed—
- Seed$5M
#12
Public · San Francisco, California · founded 2008 · 815 employees$112.9Mraised▾
Developer of genomics-based diagnostics for cancer. The company's products include the Percepta test which is used to analyze genomic alterations within epithelial cells that line the bronchial pathway to assess a patient’s risk of lung cancer and the Afirma Thyroid FNA Analysis test is used to identify benign tumor nodules. It is also developing diagnostic tests for Idiopathic Pulmonary Fibrosis(IPF) known as the Envisia classifier.
- Mar 2016Conventional Debt$45M
- Apr 2015Post IPO$40M
- Sep 2014Post IPO$12.8M
- Jun 2013Series C$28M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Clinical Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding flat · growth rising
How research on Diagnostics is moving in the United States
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 8,526 United States-affiliated papers.
- Harvard University330
- Johns Hopkins University318
- Heidelberg University249
- Massachusetts General Hospital214
- The University of Texas MD Anderson Cancer Center191
- Liquid biopsy125→427
- Biopsy15→114
- Biomarker17→103
- Point-of-care testing112→195
- Cancer67→146
- Liquid biopsy183→739
- Biopsy42→285
- Biomarker55→208
- Cancer115→260
- Oncology57→183
- Liquid biopsy67→239
- Biopsy17→99
- Biomarker28→86
- Coronavirus disease 2019 (COVID-19)1→44
- Cancer55→92
Where diagnostics is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing diagnostics patents in the United States
United States diagnostics patent filing is accelerating — 418 filings from 196 assignees (2016–2025), led by Detect, UNIV Leland Stanford Junior, Washington University ST Louis; annual filings 13→55.
- Detect42
- UNIV Leland Stanford Junior33
- Washington University ST Louis20
- Texas A & M UNIV SYS19
- UNIV California19
- Nuclein19
- Tempus LABS18
- New England Biolabs18
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.